PAMISOL

This brand name is authorized in Australia, Hong Kong, New Zealand, Singapore

Active ingredients

The drug PAMISOL contains one active pharmaceutical ingredient (API):

1 Pamidronate Disodium UNII 8742T8ZQZA - PAMIDRONATE DISODIUM

The principal pharmacologic action of pamidronic acid is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronic acid adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. Read about Pamidronate Disodium

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
M05BA03	Pamidronic acid	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 5667G, 5668H, 5669J, 5670K, 6286W, 6287X, 6288Y, 6289B, 8461H, 8462J, 8463K
Country: HK	Department of Health Drug Office	Identifier(s): 51634, 51635, 51636
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 9676, 9677, 9678
Country: SG	Health Sciences Authority	Identifier(s): 11543P, 11551P